Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions

BACKGROUND: Sorafenib is an orally administered multikinase inhibitor with antiangiogenic and antiproliferative properties. The results of large clinical trials demonstrate that sorafenib prolongs survival and the time to progression of patients with advanced hepatocellular carcinoma (HCC). The aim...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:BMC Cancer
मुख्य लेखकों: Lee, Sae Hwan, Song, Il Han, Noh, Ran, Kang, Ha Yan, Kim, Suk Bae, Ko, Soon Young, Lee, Eoum Seok, Kim, Seok Hyun, Lee, Byung Seok, Kim, An Na, Chae, Hee Bok, Kim, Hong Soo, Lee, Tae Hee, Kang, Young Woo, Lee, Jae Dong, Lee, Heon Young
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2015
विषय:
Research Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4403976/
https://ncbi.nlm.nih.gov/pubmed/25885683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1273-2
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन